This lactivity will provide VA practitioners with the latest developments and critical insights into treating their patients who have non-small cell lung cancer with an Exon 19 or 21 EGFR mutation. This education will support the interprofessional healthcare team in his/her practice setting with the essential tools to critically evaluate efficacy, safety, and clinical application.
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2024-01-05 06:00:00
- End Date: 2024-01-05 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 4996.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest